The final analysis from the phase 3 IMpassion031 trial shows that adding atezolizumab to chemotherapy for stage II/III triple-negative breast cancer is associated with favorable long-term outcomes, with circulating tumor DNA clearance correlating with therapy response.
- Elizabeth A. Mittendorf
- Zoe June Assaf
- Carlos H. Barrios
